Selinexor for Relapsed/Refractory Multiple Myeloma
AllSurvivors
Member Posts: 8
recent news item - Patients with relapsed/refractory multiple myeloma (RRMM) for whom prior treatment with lenalidomide, pomalidomide, bortezomib, and carfilzomib fail have few treatment options. Selinexor (KPT-330) is a selective inhibitor of nuclear export (SINE) under development for the treatment of RRMM and other advanced hematologic malignancies. Selinexor induces cell death through apoptosis and autophagy. This dual mechanism is both novel and potentially synergistic with mechanisms already acted upon by drugs used in the treatment of patients with RRMM. (source: mmdevelopments.org)
0
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 122K Cancer specific
- 2.8K Anal Cancer
- 446 Bladder Cancer
- 309 Bone Cancers
- 1.6K Brain Cancer
- 28.5K Breast Cancer
- 398 Childhood Cancers
- 27.9K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 13K Head and Neck Cancer
- 6.4K Kidney Cancer
- 673 Leukemia
- 794 Liver Cancer
- 4.1K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 239 Multiple Myeloma
- 7.2K Ovarian Cancer
- 65 Pancreatic Cancer
- 487 Peritoneal Cancer
- 5.5K Prostate Cancer
- 1.2K Rare and Other Cancers
- 543 Sarcoma
- 737 Skin Cancer
- 657 Stomach Cancer
- 192 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.9K Uterine/Endometrial Cancer
- 6.3K Lifestyle Discussion Boards